Resistance of Helicobacter pylori to antibiotics used in different therapeutic schemes: an integrative review: Helicobacter pylori resistance to antibiotics used in different therapeutic regimens

• Autor(a) principal: Barbosa Santiago, Silvana
• Data de Publicação: 2023
• Outros Autores: Rodrigues, Jéssica Alves, de Sousa Moraes, Felipe Augusto, Ribeiro Maximo, Gabriel, Sampaio Soares, Giovana Alice, Barbosa, Mônica Santiago
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Clinical and Biomedical Research
• Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/125639
• topic: Helicobacter pylori; Antibióticos; Tratamento.; Helicobacter pylori; Antibiotics; Treatment.

Helicobacter pylori is a gram-negative bacterium that colonizes the gastric mucosa of more than half of the world's population. Eradication is performed with first-line triple therapy to reduce the onset of infection-related gastric disease. H. pylori was considered by the World Health Organization as one of the main bacteria that need new strategies for drug development. The aim of this study was to describe the pattern of resistance of H. pylori to antibiotics used in different therapeutic regimens. This is an integrative review, whose articles were surveyed in the PubMed, LILACS, Science Direct and SciElo databases. The inclusion criteria were studies published in Portuguese and English, indexed in the last ten years, with free access in full and that addressed the theme. The results showed mean resistance rates to metronidazole of 47.6%, levofloxacin of 24.7% and clarithromycin of 24.6%. For tetracycline and amoxicillin the means were 1.5% and 0.9% respectively. These results demonstrate varying patterns of resistance and reinforce the need to develop new drugs. It is concluded that the abusive use of antibiotics has led to increased resistance of H. pylori to the antibiotics used in its eradication.